Merck, NewLink Genetics ink licensing deal for investigational Ebola vaccine
rVSV-EBOV was originally developed by the Public Health Agency of Canada (PHAC) and is currently being evaluated in Phase I clinical trials. Merck Vaccines president Dr Julie Gerberding
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.